Moreover, FVIII expression in hemophilia A gene therapy tends to gradually decrease over time compared to that in hemophilia B. Hemophilia A gene therapy also required the administration of huge amounts of AAV vectors in clinical trials, even though the molar concentration of FVIII is much lower than that of FIX33. This evidence concerns the gene F8 and hemophilia B.